Background:
The HIV pandemic affects 36·9 million people worldwide, of whom 1·5 million are pregnant women. 91% of HIV-positive pregnant women reside in sub-Saharan Africa, a region that also has very poor perinatal outcomes. We aimed to establish whether untreated maternal HIV infection is associated with specific perinatal outcomes.
Methods:
We did a systematic review and meta-analysis of the scientific literature by searching PubMed, CINAHL (Ebscohost), Global Health (Ovid), EMBASE (Ovid), and the Cochrane Central Register of Controlled Trials and four clinical trial databases (WHO International Clinical Trials Registry Platform, the Pan African Clinical Trials Registry, the ClinicalTrials.gov database, and the ISRCTN Registry) for studies published from Jan 1, 1980, to Dec 7, 2014. Two authors independently reviewed the studies retrieved by the scientific literature search, identified relevant studies, and extracted the data. We investigated the associations between maternal HIV infection in women naive to antiretroviral therapy and 11 perinatal outcomes: preterm birth, very preterm birth, low birthweight, very low birthweight, term low birthweight, preterm low birthweight, small for gestational age, very small for gestational age, miscarriage, stillbirth, and neonatal death. We included prospective and retrospective cohort studies and case-control studies reporting perinatal outcomes in HIV-positive women naive to antiretroviral therapy and HIV-negative controls. We used a random-effects model for the meta-analyses of specific perinatal outcomes. We did subgroup and sensitivity analyses and assessed the effect of adjustment for confounders. This systematic review and meta-analysis is registered with PROSPERO, number CRD42013005638.
Findings:
Of 60,750 studies identified, we obtained data from 35 studies (20 prospective cohort studies, 12 retrospective cohort studies, and three case-control studies) including 53 623 women. Our meta-analyses of prospective cohort studies show that maternal HIV infection is associated with an increased risk of preterm birth (relative risk 1·50, 95% CI 1·24-1·82), low birthweight (1·62, 1·41-1·86), small for gestational age (1·31, 1·14-1·51), and stillbirth (1·67, 1·05-2·66). Retrospective cohort studies also suggest an increased risk of term low birthweight (2·62, 1·15-5·93) and preterm low birthweight (3·25, 2·12-4·99). The strongest and most consistent evidence for these associations is identified in sub-Saharan Africa. No association was identified between maternal HIV infection and very preterm birth, very small for gestational age, very low birthweight, miscarriage, or neonatal death, although few data were available for these outcomes. Correction for confounders did not affect the significance of these findings.
Interpretation:
Maternal HIV infection in women who have not received antiretroviral therapy is associated with preterm birth, low birthweight, small for gestational age, and stillbirth, especially in sub-Saharan Africa. Research is needed to assess how antiretroviral therapy regimens affect these perinatal outcomes.
Funding:
None.
Citing Articles
Antiretroviral drug exposure in pregnancy and risk of congenital anomalies: a European case/non-case malformed study.
Saint-Lary L, Beau A, Sommet A, Leroy V, Loane M, Cavero-Carbonell C
Eur J Clin Pharmacol. 2025; .
PMID: 40011239
DOI: 10.1007/s00228-025-03814-w.
Perinatal outcomes among pregnant women with HIV initiating antiretroviral therapy preconception and antenatally.
Boering P, Murray C, Portwood C, Hey M, Thompson L, Beck K
AIDS. 2025; 39(5):584-596.
PMID: 39760703
PMC: 11902611.
DOI: 10.1097/QAD.0000000000004104.
Subsequent pregnancies in the IMPAACT 2010/VESTED Trial: high rate of adverse outcomes in women living with HIV.
Fairlie L, Brummel S, Ziemba L, Coletti A, Chinula L, Shapiro R
J Acquir Immune Defic Syndr. 2025; 97(2):150-155.
PMID: 39742354
PMC: 11684739.
DOI: 10.1097/qai.0000000000003473.
Adverse birth outcome research case definitions associated with maternal HIV and antiretroviral drug use in pregnancy: a scoping review.
Dube K, de Beer S, Powis K, McCaul M, Slogrove A
BMC Pregnancy Childbirth. 2024; 24(1):844.
PMID: 39709379
PMC: 11662713.
DOI: 10.1186/s12884-024-06939-5.
Role of Dolutegravir/Lamivudine in the Management of Pregnant People Living with HIV-1: A Narrative Review.
Short W, Patel P, Verdier G, Puga A, Vannappagari V, de Ruiter A
Infect Dis Ther. 2024; 14(1):59-80.
PMID: 39652285
PMC: 11782740.
DOI: 10.1007/s40121-024-01085-z.
Facilitators and Barriers of Implementing Expanded Sexually Transmitted Infection Screening in California Family Planning Clinics.
Ehlers E, Kovaleski L, Devaskar S, Kennedy S, Plotzker R
Sex Transm Dis. 2024; 52(1):9-13.
PMID: 39651779
PMC: 11631046.
DOI: 10.1097/OLQ.0000000000002072.
Risk factors of under-five and infant mortality: An umbrella review of systematic reviews and meta-analyses.
Kefale B, Jancey J, Gebremedhin A, Nyadanu S, Belay D, Pereira G
J Glob Health. 2024; 14:04260.
PMID: 39611446
PMC: 11605776.
DOI: 10.7189/jogh.14.04260.
Care of the Child Perinatally Exposed to Human Immunodeficiency Virus.
Wedderburn C, Musiime G, McHenry M
Clin Perinatol. 2024; 51(4):881-894.
PMID: 39487026
PMC: 11781781.
DOI: 10.1016/j.clp.2024.08.011.
Adverse perinatal outcomes associated with different classes of antiretroviral drugs in pregnant women with HIV.
Hey M, Thompson L, Portwood C, Sexton H, Kumarendran M, Brandon Z
AIDS. 2024; 39(2):162-174.
PMID: 39407417
PMC: 11676599.
DOI: 10.1097/QAD.0000000000004032.
The Negative Impact of Maternal HIV Infection on Birth Outcomes-Myth or Reality?.
Fleseriu T, Melit L, Marginean C, Vasiesiu A
Pathogens. 2024; 13(9).
PMID: 39338999
PMC: 11434926.
DOI: 10.3390/pathogens13090808.
Interpregnancy interval, air pollution, and the risk of low birth weight: a retrospective study in China.
Lu X, Zhang Y, Jiang R, Qin G, Ge Q, Zhou X
BMC Public Health. 2024; 24(1):2529.
PMID: 39289643
PMC: 11409551.
DOI: 10.1186/s12889-024-19711-3.
Predictors of low birthweight and comparisons of newborn birthweights among different groups of maternal factors at Rev. John Chilembwe Hospital in Phalombe district, Malawi: A retrospective record review.
Mfipa D, Hajison P, Mpachika-Mfipa F
PLoS One. 2024; 19(8):e0291585.
PMID: 39208326
PMC: 11361679.
DOI: 10.1371/journal.pone.0291585.
Maternal and Newborn Outcomes of SARS-CoV-2/COVID-19 and Pregnancy: Parallels and Contrasts with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome.
Li D, Zhang J, Zhang X, Chang Y, Vermund S
Med Res Arch. 2024; 12(4).
PMID: 39118854
PMC: 11309002.
DOI: 10.18103/mra.v12i4.5205.
Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non-case study from the global pharmacovigilance database VigiBase®.
Saint-Lary L, Lacroix I, Leroy V, Sommet A
Pharmacol Res Perspect. 2024; 12(4):e1247.
PMID: 39086081
PMC: 11291555.
DOI: 10.1002/prp2.1247.
Fetal, neonatal, and infant death among offspring of pregnant women with HIV in Tanzania.
Manji K, Muhihi A, Duggan C, Alwy Al-Beity F, Perumal N, Ulenga N
AIDS. 2024; 38(14):1947-1955.
PMID: 39082366
PMC: 11524766.
DOI: 10.1097/QAD.0000000000003985.
Preterm birth among women with HIV: impact of preconception cART initiation.
Duffy C, Herlihy J, Zulu E, Mwananyanda L, Forman L, Heeren T
AIDS. 2024; 38(12):1749-1757.
PMID: 39017638
PMC: 11356690.
DOI: 10.1097/QAD.0000000000003979.
How much could anemia-related interventions reduce the HIV disparity in adverse birth outcomes?.
Caniglia E, Zash R, Diseko M, Mayondi G, Mabuta J, Mmalane M
Am J Epidemiol. 2024; 194(1):122-131.
PMID: 38965743
PMC: 11735963.
DOI: 10.1093/aje/kwae160.
Fetal Clinical and Paraclinical Outcomes in HIV-Positive Pregnant Women.
Iordache M, Meca D, Cirstoiu M
Cureus. 2024; 16(5):e59568.
PMID: 38826912
PMC: 11144293.
DOI: 10.7759/cureus.59568.
Contribution of Syphilis to Adverse Pregnancy Outcomes in People Living With and Without HIV in South Brazil: 2008 to 2018.
Yang L, Sundar K, Cambou M, Swayze E, Segura E, de Melo M
Sex Transm Dis. 2024; 51(10):659-666.
PMID: 38691407
PMC: 11472861.
DOI: 10.1097/OLQ.0000000000001993.
Perinatal outcomes associated with pre-exposure prophylaxis for HIV prevention during pregnancy: a systematic review and meta-analysis.
Erlwanger A, Rocroi I, Kirtley S, Hemelaar J
EClinicalMedicine. 2024; 70:102532.
PMID: 38685925
PMC: 11056414.
DOI: 10.1016/j.eclinm.2024.102532.